available for iOS, Android & web
August 19, 2013
Approved in combination with Roche's Herceptin for advanced breast cancer
June 28, 2012
There will no doubt be disappointment on final guidance from NICE this week rejecting the use of GlaxoSmithKline's Tyverb and Roche's Herceptin for a subset of patients with breast cancer on the National Health Service.
February 14, 2012
Cost regulators for the National Health Service in England and Wales are sticking with their initial decision to reject the use of GlaskoSmithKline's Tyverb and Roche's Herceptin alongside hormone therapy in certain postmenopausal breast cancer patients.
December 09, 2011
GlaxoSmithKline has suffered a setback with the news that Tykerb has failed a late-stage study investigating whether adjuvant treatment with the drug will improve disease-free survival in women with early-stage HER2 positive breast cancer.
October 14, 2010
GSK has lost its appeal to overturn NICE draft guidance on the use of Tyverb in National Health Service patients with breast cancer, but the Institute wants to consider the drug in a different appraisal alongside Roche's Herceptin instead.
Recruitment agencies provide the unique bridge to [more]...
International Clinical Researcher of the Year 2016
Book your tickets today!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions